Annual FCF
$12.42 M
-$18.89 M-60.33%
31 December 2023
Summary:
Vanda Pharmaceuticals annual free cash flow is currently $12.42 million, with the most recent change of -$18.89 million (-60.33%) on 31 December 2023. During the last 3 years, it has fallen by -$37.56 million (-75.15%). VNDA annual FCF is now -92.11% below its all-time high of $157.34 million, reached on 31 December 2009.VNDA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$14.74 M
-$7.71 M-109.52%
30 September 2024
Summary:
Vanda Pharmaceuticals quarterly free cash flow is currently -$14.74 million, with the most recent change of -$7.71 million (-109.52%) on 30 September 2024. Over the past year, it has dropped by -$12.67 million (-610.80%). VNDA quarterly FCF is now -108.00% below its all-time high of $184.29 million, reached on 31 December 2009.VNDA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$18.20 M
-$12.67 M-228.95%
30 September 2024
Summary:
Vanda Pharmaceuticals TTM free cash flow is currently -$18.20 million, with the most recent change of -$12.67 million (-228.95%) on 30 September 2024. Over the past year, it has dropped by -$43.76 million (-171.22%). VNDA TTM FCF is now -110.20% below its all-time high of $178.49 million, reached on 30 September 2010.VNDA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VNDA Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -60.3% | -610.8% | -171.2% |
| 3 y3 years | -75.2% | -256.7% | -132.8% |
| 5 y5 years | +168.9% | -358.4% | -136.1% |
VNDA Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -80.5% | at low | -146.4% | at low | -128.6% | at low |
| 5 y | 5 years | -80.5% | +168.9% | -146.4% | at low | -128.6% | at low |
| alltime | all time | -92.1% | +113.8% | -108.0% | +60.1% | -110.2% | +80.1% |
Vanda Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.74 M(+109.5%) | -$18.20 M(+229.0%) |
| June 2024 | - | -$7.04 M(-193.0%) | -$5.53 M(-53.0%) |
| Mar 2024 | - | $7.56 M(-289.8%) | -$11.77 M(-194.8%) |
| Dec 2023 | $12.42 M(-60.3%) | -$3.98 M(+92.1%) | $12.42 M(-51.4%) |
| Sept 2023 | - | -$2.07 M(-84.4%) | $25.56 M(-36.6%) |
| June 2023 | - | -$13.28 M(-141.8%) | $40.32 M(-31.8%) |
| Mar 2023 | - | $31.75 M(+246.9%) | $59.09 M(+88.7%) |
| Dec 2022 | $31.30 M(-50.8%) | $9.15 M(-27.9%) | $31.30 M(-35.6%) |
| Sept 2022 | - | $12.69 M(+131.0%) | $48.63 M(+7.2%) |
| June 2022 | - | $5.49 M(+38.3%) | $45.34 M(-22.6%) |
| Mar 2022 | - | $3.97 M(-85.0%) | $58.57 M(-8.0%) |
| Dec 2021 | $63.66 M(+27.4%) | $26.47 M(+181.4%) | $63.66 M(+14.7%) |
| Sept 2021 | - | $9.41 M(-49.7%) | $55.52 M(+0.5%) |
| June 2021 | - | $18.72 M(+106.5%) | $55.25 M(-8.4%) |
| Mar 2021 | - | $9.06 M(-50.6%) | $60.32 M(+20.7%) |
| Dec 2020 | $49.98 M(+11.2%) | $18.34 M(+100.9%) | $49.98 M(+20.8%) |
| Sept 2020 | - | $9.13 M(-61.6%) | $41.37 M(+9.0%) |
| June 2020 | - | $23.80 M(-1959.1%) | $37.94 M(+10.3%) |
| Mar 2020 | - | -$1.28 M(-113.2%) | $34.40 M(-23.4%) |
| Dec 2019 | $44.93 M(+872.9%) | $9.72 M(+70.5%) | $44.93 M(-10.9%) |
| Sept 2019 | - | $5.70 M(-71.8%) | $50.45 M(-5.4%) |
| June 2019 | - | $20.25 M(+118.9%) | $53.30 M(+331.1%) |
| Mar 2019 | - | $9.25 M(-39.3%) | $12.37 M(+167.8%) |
| Dec 2018 | $4.62 M(-226.6%) | $15.24 M(+78.1%) | $4.62 M(-162.8%) |
| Sept 2018 | - | $8.56 M(-141.4%) | -$7.35 M(-47.9%) |
| June 2018 | - | -$20.68 M(-1476.2%) | -$14.11 M(-482.3%) |
| Mar 2018 | - | $1.50 M(-54.1%) | $3.69 M(-201.2%) |
| Dec 2017 | -$3.65 M(-61.7%) | $3.27 M(+82.2%) | -$3.65 M(-58.6%) |
| Sept 2017 | - | $1.80 M(-162.3%) | -$8.80 M(-11.6%) |
| June 2017 | - | -$2.88 M(-50.6%) | -$9.96 M(-4.7%) |
| Mar 2017 | - | -$5.83 M(+210.4%) | -$10.45 M(+9.8%) |
| Dec 2016 | -$9.51 M(-195.8%) | -$1.88 M(-392.8%) | -$9.51 M(+9.3%) |
| Sept 2016 | - | $642.00 K(-119.0%) | -$8.70 M(-42.3%) |
| June 2016 | - | -$3.37 M(-31.1%) | -$15.07 M(-6102.8%) |
| Mar 2016 | - | -$4.90 M(+357.9%) | $251.00 K(-97.5%) |
| Dec 2015 | $9.92 M(-111.0%) | -$1.07 M(-81.3%) | $9.92 M(-463.2%) |
| Sept 2015 | - | -$5.72 M(-147.9%) | -$2.73 M(-41.4%) |
| June 2015 | - | $11.95 M(+150.3%) | -$4.66 M(-91.3%) |
| Mar 2015 | - | $4.77 M(-134.8%) | -$53.51 M(-40.8%) |
| Dec 2014 | -$90.32 M | -$13.72 M(+79.4%) | -$90.32 M(+1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2014 | - | -$7.65 M(-79.3%) | -$88.85 M(-2.9%) |
| June 2014 | - | -$36.91 M(+15.2%) | -$91.47 M(+46.0%) |
| Mar 2014 | - | -$32.04 M(+161.5%) | -$62.66 M(+57.6%) |
| Dec 2013 | -$39.77 M(-15.3%) | -$12.25 M(+19.2%) | -$39.77 M(-3.9%) |
| Sept 2013 | - | -$10.28 M(+27.0%) | -$41.37 M(+0.2%) |
| June 2013 | - | -$8.09 M(-11.5%) | -$41.28 M(-9.4%) |
| Mar 2013 | - | -$9.15 M(-34.0%) | -$45.55 M(-3.0%) |
| Dec 2012 | -$46.93 M(+63.6%) | -$13.86 M(+36.1%) | -$46.93 M(+3.1%) |
| Sept 2012 | - | -$10.18 M(-17.6%) | -$45.51 M(+7.0%) |
| June 2012 | - | -$12.36 M(+17.3%) | -$42.53 M(+18.3%) |
| Mar 2012 | - | -$10.54 M(-15.3%) | -$35.96 M(+25.3%) |
| Dec 2011 | -$28.68 M(+163.2%) | -$12.43 M(+72.6%) | -$28.68 M(+34.4%) |
| Sept 2011 | - | -$7.20 M(+24.6%) | -$21.35 M(+11.1%) |
| June 2011 | - | -$5.78 M(+77.2%) | -$19.22 M(+105.8%) |
| Mar 2011 | - | -$3.26 M(-35.9%) | -$9.34 M(-14.3%) |
| Dec 2010 | -$10.90 M(-106.9%) | -$5.10 M(+0.4%) | -$10.90 M(-106.1%) |
| Sept 2010 | - | -$5.07 M(-223.8%) | $178.49 M(+2.1%) |
| June 2010 | - | $4.10 M(-184.9%) | $174.85 M(+11.9%) |
| Mar 2010 | - | -$4.83 M(-102.6%) | $156.30 M(-0.7%) |
| Dec 2009 | $157.34 M(-435.5%) | $184.29 M(-2214.8%) | $157.34 M(-585.5%) |
| Sept 2009 | - | -$8.71 M(-39.7%) | -$32.41 M(-13.5%) |
| June 2009 | - | -$14.45 M(+280.7%) | -$37.44 M(+8.9%) |
| Mar 2009 | - | -$3.79 M(-30.4%) | -$34.40 M(-26.7%) |
| Dec 2008 | -$46.90 M(-9.7%) | -$5.45 M(-60.4%) | -$46.90 M(-19.3%) |
| Sept 2008 | - | -$13.75 M(+20.6%) | -$58.10 M(+5.2%) |
| June 2008 | - | -$11.40 M(-30.0%) | -$55.21 M(+0.9%) |
| Mar 2008 | - | -$16.30 M(-2.1%) | -$54.69 M(+5.3%) |
| Dec 2007 | -$51.92 M(-2.0%) | -$16.65 M(+53.3%) | -$51.92 M(+11.5%) |
| Sept 2007 | - | -$10.86 M(-0.2%) | -$46.55 M(-12.0%) |
| June 2007 | - | -$10.88 M(-19.5%) | -$52.93 M(-4.5%) |
| Mar 2007 | - | -$13.52 M(+19.9%) | -$55.42 M(+4.6%) |
| Dec 2006 | -$52.97 M(+194.2%) | -$11.28 M(-34.6%) | -$52.97 M(+10.9%) |
| Sept 2006 | - | -$17.24 M(+28.9%) | -$47.79 M(+36.1%) |
| June 2006 | - | -$13.37 M(+20.7%) | -$35.11 M(+38.0%) |
| Mar 2006 | - | -$11.08 M(+81.7%) | -$25.45 M(+41.4%) |
| Dec 2005 | -$18.01 M(+99.4%) | -$6.10 M(+33.5%) | -$18.01 M(+51.2%) |
| Sept 2005 | - | -$4.57 M(+23.0%) | -$11.91 M(+62.2%) |
| June 2005 | - | -$3.71 M(+2.3%) | -$7.34 M(+102.3%) |
| Mar 2005 | - | -$3.63 M | -$3.63 M |
| Dec 2004 | -$9.03 M | - | - |
FAQ
- What is Vanda Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual FCF year-on-year change?
- What is Vanda Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly FCF year-on-year change?
- What is Vanda Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals TTM FCF year-on-year change?
What is Vanda Pharmaceuticals annual free cash flow?
The current annual FCF of VNDA is $12.42 M
What is the all time high annual FCF for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual free cash flow is $157.34 M
What is Vanda Pharmaceuticals annual FCF year-on-year change?
Over the past year, VNDA annual free cash flow has changed by -$18.89 M (-60.33%)
What is Vanda Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of VNDA is -$14.74 M
What is the all time high quarterly FCF for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly free cash flow is $184.29 M
What is Vanda Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, VNDA quarterly free cash flow has changed by -$12.67 M (-610.80%)
What is Vanda Pharmaceuticals TTM free cash flow?
The current TTM FCF of VNDA is -$18.20 M
What is the all time high TTM FCF for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high TTM free cash flow is $178.49 M
What is Vanda Pharmaceuticals TTM FCF year-on-year change?
Over the past year, VNDA TTM free cash flow has changed by -$43.76 M (-171.22%)